

FIRST LIGHT

16 February 2023

RESEARCH

SIEMENS INDIA | TARGET: Rs 3,800 | +22% | BUY

Stellar quarter

PI INDUSTRIES | TARGET: Rs 3,800 | +22% | BUY

Strong quarter spurred by custom synthesis business

CESC | TARGET: Rs 108 | +44% | BUY

Stable performance; DF circles disappoint

CONSUMER DURABLES | Q3FY23 REVIEW

Margin recovery delayed

SUMMARY

SIEMENS INDIA

- Strong Q1 beat aided by margin expansion across segments. C&S Electric turns a corner
- Parent's upward guidance revision for SI and DI businesses signals margin expansion opportunities for India entity
- Execution momentum set to continue; retain BUY with a revised TP of Rs 3,800 (vs. Rs 3,500) on rollover

[Click here for the full report.](#)

PI INDUSTRIES

- Q3 robust with EBITDA/PAT growth of 40%/58% YoY on the back of margin improvement, low tax and higher other income
- Favourable product mix (82% CSM share) and operating leverage fuelled EBITDA margin expansion of 385bps YoY to 25.7%
- We raise FY23-FY24 EBITDA by 8-11% and roll over to a revised TP of Rs 3,800 (vs. Rs 3,020); maintain BUY

[Click here for the full report.](#)

Daily macro indicators

Indicator	13-Feb	14-Feb	Chg (%)
US 10Y yield (%)	3.70	3.74	4bps
India 10Y yield (%)	7.37	7.37	0bps
USD/INR	82.73	82.76	0.0
Brent Crude (US\$/bbl)	86.6	85.6	(1.2)
Dow	34,246	34,089	(0.5)
Hang Seng	21,164	21,114	(0.2)
Sensex	60,432	61,032	1.0
India FII (US\$ mn)	10-Feb	13-Feb	Chg (\$ mn)
FII-D	32.1	91.0	58.9
FII-E	209.0	181.0	(28.0)

Source: Bank of Baroda Economics Research

BOBCAPS Research

research@bobcaps.in



CESC

- Stable Q3 with 4% YoY revenue growth to Rs 19bn and flattish net profit at Rs 1.9bn
- Distribution franchisee (DF) circles in Rajasthan and Malegaon continue to disappoint as losses widened
- Stock at attractive valuations of 0.8x FY25E P/BV with dividend yield at 6%; retain BUY with an unchanged TP of Rs 108

[Click here](#) for the full report.

CONSUMER DURABLES: Q3FY23 REVIEW

- Consumer durables players posted modest topline growth in Q3 as volumes moved up but pricing action faltered
- Margins recovered sequentially on exhaustion of high-cost inventory, raising hopes of a revival
- We maintain our top picks – HAVL, CROMPTON and POLYCAB

[Click here](#) for the full report.

BUY**TP: Rs 3,800 | ▲ 22%****SIEMENS INDIA**

Capital Goods

15 February 2023

Stellar quarter

- **Strong Q1 beat aided by margin expansion across segments. C&S Electric turns a corner**
- **Parent's upward guidance revision for SI and DI businesses signals margin expansion opportunities for India entity**
- **Execution momentum set to continue; retain BUY with a revised TP of Rs 3,800 (vs. Rs 3,500) on rollover**

Vinod Chari | Tanay Rasal

Nilesh Patil

research@bobcaps.in

Strong Q1 beat: SIEM reported a stellar EBITDA margin of 14.9%, up 470bps YoY in Q1FY23 (Sep Y/E) and beating our estimate of 10.7%, aided by margin gains across segments. Execution was steady, fuelling a 13% YoY rise in revenue to Rs 40bn as the smart infrastructure business grew 18% (to Rs 15.2bn) and digital industries grew 29% (to Rs 10.2bn). Net profit surged 85% YoY to Rs 4.6bn (Rs 3.2bn est.)

C&S turns a corner: C&S Electric's revenue grew 14% YoY to Rs 3.3bn. Notably, the company achieved an EBIT margin of 3.4% and EBIT of Rs 114mn, a significant improvement compared to a loss of Rs 15mn in Q1FY22. With its strong low-voltage portfolio, we expect C&S to have a more substantial presence in export markets.

DI and SI key to margin expansion: Parent Siemens AG's focus on software-as-a-service (SaaS) is expected to boost margins of its digital industries (DI) business. Over the next 3-5 years, this move is likely to benefit India operations as the company looks to monetise its software offerings. Further, Siemens AG's recent upward revision of its DI growth guidance by 2ppt to 12-15% and EBIT margin guidance by 100bps to 20-22% for FY23 is a positive sign for the India arm.

We anticipate growth from digitalisation services in building technologies, alongside higher margins in low-voltage products and a favourable product mix in electrification and switchgears (SF6-free). In addition, C&S Electric's EBIT turnaround post-acquisition and the parent's positive revision in growth guidance for the smart infrastructure (SI) business by 1ppt to 9-12% and margin guidance by 50bps to 13.5-14.5% for FY23 should boost outsourcing to low-cost markets such as India.

Maintain BUY: SIEM is benefiting from structural tailwinds in its digitalisation and automation businesses, as well as traction in the previously underperforming mobility segment. The company is also well positioned to harness the opportunities from green energy transition. We tweak estimates and roll valuations forward to Dec'24E, translating to a revised TP of Rs 3,800 (vs. Rs 3,500), valuing the stock at an unchanged 57x P/E – a 30% premium to the 5Y average. BUY.

Key changes

Target	Rating
▲	◀ ▶


Ticker/Price	SIEM IN/Rs 3,125
Market cap	US\$ 13.4bn
Free float	25%
3M ADV	US\$ 15.3mn
52wk high/low	Rs 3,174/Rs 2,150
Promoter/FPI/DII	75%/5%/10%

Source: NSE | Price as of 14 Feb 2023

Key financials

Y/E 30 Sep	FY22A	FY23E	FY24E
Total revenue (Rs mn)	1,61,378	1,96,656	2,33,094
EBITDA (Rs mn)	17,573	23,402	28,965
Adj. net profit (Rs mn)	12,619	17,228	21,853
Adj. EPS (Rs)	35.4	48.4	61.4
Consensus EPS (Rs)	35.4	47.3	61.9
Adj. ROAE (%)	11.5	14.1	16.1
Adj. P/E (x)	88.2	64.6	50.9
EV/EBITDA (x)	66.2	50.4	40.8
Adj. EPS growth (%)	22.5	36.5	26.8

Source: Company, Bloomberg, BOBCAPS Research

Stock performance

Source: NSE



BUY**TP: Rs 3,800 | ▲ 22%****PI INDUSTRIES**

| Agrochemicals

| 15 February 2023

Strong quarter spurred by custom synthesis business

- Q3 robust with EBITDA/PAT growth of 40%/58% YoY on the back of margin improvement, low tax and higher other income
- Favourable product mix (82% CSM share) and operating leverage fuelled EBITDA margin expansion of 385bps YoY to 25.7%
- We raise FY23-FY24 EBITDA by 8-11% and roll over to a revised TP of Rs 3,800 (vs. Rs 3,020); maintain BUY

Saad Shaikh

research@bobcaps.in

Revenue growth spurred by CSM: PI reported 19% YoY growth in Q3FY23 revenue to Rs 16bn driven purely by the export business which grew 23%. Volumes/pricing grew 9%/14%, with the latter also supported by favourable currency movement. Management expects the scale up of existing products, 4-5 new commercialisations a year, and steady flow of enquiries to support future growth.

Sharp sequential decline in domestic business: Domestic business dropped 42% QoQ, albeit on a high base of Q2, due to a demand slowdown (on account of adverse weather conditions) and higher channel inventory. PI is confident of double-digit growth in India business during FY24 based on launches over the last 2-3 years.

Better product mix and operating leverage helped margins: Gross margin expanded 70bps YoY (+200bps QoQ) as the product mix shifted in favour of custom synthesis manufacturing (CSM: 82% of revenue). This along with operating leverage took EBITDA margin to 25.7%, up 385bps YoY (+130bps QoQ). Margin improvement coupled with a lower tax rate of 12.1% (vs. 17.3%/15.9% in Q3FY22/Q2FY23) and higher other income fuelled strong 58% YoY growth in net income to Rs 3.5bn.

Earnings call highlights: (1) PI's export order book stands at ~US\$ 1.8bn. (2) About 40 products are at different development stages (17+ in agrochemicals). (3) Operating cash flow stood at Rs 6.8bn in Q3 (Rs 10bn in 9MFY23). Cash on books was at Rs 29bn. (4) PI maintained its revenue guidance of 20%+ and indicated plans to intensify capacity expansion via capex of Rs 8bn-8.5bn in FY24.

Maintain BUY: Based on the 9MFY23 print, we raise FY23-FY24 EBITDA estimates 8-11%. This along with rollover of valuations to FY25E yields a new TP of Rs 3,800 (vs. Rs 3,020), which is set at 25x EV/EBITDA – in line with the stock's 5Y average. We expect PI's differentiated capabilities in the CSM export segment (US\$ 1.8bn order book) and launch pipeline in India to drive 25%+ EPS growth and 30%+ ROIC over FY22-FY25. The company has performed well in 9MFY23 on a high revenue base and shown resilience on the margin front by passing along costs and improving its product mix. Retain BUY.

Key changes

Target	Rating
▲	◀ ▶

Ticker/Price	PI IN/Rs 3,122
Market cap	US\$ 5.7bn
Free float	53%
3M ADV	US\$ 11.8mn
52wk high/low	Rs 3,698/Rs 2,351
Promoter/FPI/DII	46%/19%/24%


Source: NSE | Price as of 15 Feb 2023

Key financials

Y/E 31 Mar	FY22A	FY23E	FY24E
Total revenue (Rs mn)	52,995	65,589	77,136
EBITDA (Rs mn)	11,424	15,376	18,298
Adj. net profit (Rs mn)	8,438	11,971	14,029
Adj. EPS (Rs)	55.7	79.0	92.5
Consensus EPS (Rs)	55.7	77.0	94.4
Adj. ROAE (%)	14.5	17.8	17.9
Adj. P/E (x)	56.1	39.5	33.7
EV/EBITDA (x)	40.3	29.3	24.5
Adj. EPS growth (%)	14.3	41.9	17.2

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE



BUY

TP: Rs 108 | ▲ 44%

CESC

| Power

| 15 February 2023

Stable performance; DF circles disappoint

- **Stable Q3 with 4% YoY revenue growth to Rs 19bn and flattish net profit at Rs 1.9bn**
- **Distribution franchisee (DF) circles in Rajasthan and Malegaon continue to disappoint as losses widened**
- **Stock at attractive valuations of 0.8x FY25E P/BV with dividend yield at 6%; retain BUY with an unchanged TP of Rs 108**

Anupam Goswami

research@bobcaps.in

Flat performance: CESC's standalone Q3FY23 net revenue (including regulated income) grew 4% YoY to Rs 19bn, slightly above our estimate. Standalone EBITDA including regulatory income increased 10% YoY to Rs 4.5bn. The company posted regulatory income of only Rs 2.3bn during the quarter as against Rs 2bn in the year-ago period. Standalone net income was flat YoY at Rs 1.9bn (Rs 1.7 bn est.). On a consolidated basis, revenue grew 11% YoY to Rs 31bn, EBITDA (incl. regulatory income) was flat at Rs 8.3bn and net income was also flat at Rs 3.4bn.

Demand stable due to early winter in Kolkata circle: Power sales during Q3FY23 stood at 2,201MU, an increase of only 2.6% YoY.

Losses in DF circles widen: CESC's Rajasthan distribution franchisees (DF) continued to post losses in 9MFY23 at Rs 290mn vs. Rs 190mn in 9MFY22. Malegaon DF losses also widened to Rs 670mn from Rs 410mn.

Dhariwal performance has stabilised: PLF (plant load factor) for subsidiary Dhariwal Infrastructure stood at 80% vs. 63.4% in Q3FY22 on the back of a three-year power purchase agreement (PPA) for Unit-1. Net profit for 9MFY23 came in higher at Rs 1.7bn compared to Rs 1.1bn in the corresponding year-ago period.

Retain BUY: CESC's generation and distribution assets in Kolkata remain a cash cow for the company, producing strong cash flows and high ROE. A steady performance at Dhariwal due to the new PPA should continue to broaden earnings visibility and cash generation. This apart, CESC's dividend yield is high at 6%, and we find current valuations attractive at 0.8x FY25E P/BV. We thus maintain BUY with an unchanged SOTP-based TP of Rs 108 for 44% upside potential. Turnaround in DF circles, however, remains a key monitorable.

Key changes

Target	Rating
◀ ▶	◀ ▶

Ticker/Price	CESC IN/Rs 75
Market cap	US\$ 1.2bn
Free float	48%
3M ADV	US\$ 1.8mn
52wk high/low	Rs 88/Rs 68
Promoter/FPI/DII	52%/13%/35%


Source: NSE | Price as of 14 Feb 2023

Key financials

Y/E 31 Mar	FY22A	FY23E	FY24E
Total revenue (Rs mn)	1,32,810	1,42,934	1,45,859
EBITDA (Rs mn)	36,540	37,161	38,092
Adj. net profit (Rs mn)	14,026	15,829	16,783
Adj. EPS (Rs)	10.5	11.9	12.6
Consensus EPS (Rs)	10.5	11.6	12.1
Adj. ROAE (%)	13.5	14.3	14.2
Adj. P/E (x)	7.1	6.3	6.0
EV/EBITDA (x)	5.9	5.9	5.5
Adj. EPS growth (%)	2.1	12.9	5.9

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE



CONSUMER DURABLES

Q3FY23 Review

15 February 2023

Margin recovery delayed

- Consumer durables players posted modest topline growth in Q3 as volumes moved up but pricing action faltered
- Margins recovered sequentially on exhaustion of high-cost inventory, raising hopes of a revival
- We maintain our top picks – HAVL, CROMPTON and POLYCAB

Vinod Chari | Nilesh Patil
 Tanay Rasal
 research@bobcaps.in

Topline intact but margins stressed: Our consumer durables universe posted modest topline growth of 10% YoY in Q3FY23 against our estimate of 14% (ex-DIXON), reinforcing our thesis of volume over value growth as all players refrained from taking price hikes. EBITDA margins, however, remained weak, dashing industry hopes of recovery from H2FY23 onwards. Players expect a better Q4FY23, laying the foundation for price hikes and margin recovery thereafter.

Traction in fans: Most companies posted strong growth in the fans business, particularly for lower-end products, as distributors pushed sales of non-compliant fan inventory at discounted prices ahead of BEE rating transition. In contrast, market leader CROMPTON chose to focus on its new star-rated fans, dampening growth.

RAC players pin hopes on a better summer season: RAC players reported resilient Q3 sales amidst a seasonally weak period and subdued demand. However, margin pressure persisted (ex-BLSTR). The industry outlook for the upcoming summer season remains optimistic, with expectations of higher volumes and price hikes.

Margin recovery likely: In line to our thesis, our coverage basket saw EBITDA margins deteriorating YoY but expanding sequentially (barring VOLT & VGRD). Margins were muted by high-cost inventory & rebound in commodity prices late in quarter. We expect margin recovery in core CD pack ahead as most of expensive inventory has been exhausted & commentary points to price hikes in Q4FY23.

EMS traction continues: Our EMS basket clocked strong topline growth YoY (ex-DIXON) and robust order booking, implying continued traction in the near future. While AMBER and SYRMA beat our topline estimates but saw muted margins, DIXON recorded a lower topline but better margin. DIXON's steep cut in topline guidance and delays in mobile client addition make for an uncertain near-term outlook.

Retain top picks: Barring DIXON, our top picks remain intact following target price adjustments due to valuation rollover and Q3 performance. We retain our positive bias on [HAVL](#) (TP Rs 1,500), [CROMPTON](#) (TP Rs 440, BUY), and [POLYCAB](#) (TP Rs 3,300).

Recommendation snapshot

Ticker	Price	Target	Rating
AMBER IN	1,857	2,100	HOLD
BLSTR IN	1,385	1,450	BUY
CROMPTON IN	305	440	BUY
DIXON IN	2,702	4,100	BUY
HAVL IN	1,218	1,500	BUY
KEII IN	1,613	1,900	BUY
ORIENTEL IN	273	290	HOLD
POLYCAB IN	3,006	3,300	BUY
SYRMA IN	264	400	BUY
VGRD IN	246	260	HOLD
VOLT IN	859	910	HOLD

Price & Target in Rupees | Price as of 15 Feb 2023

Consumer durables: Q3 result reviews

Company	Result review link
AMBER IN	Strong topline but margins remain muted
BLSTR IN	Buoyant performance; UCP margin expansion continues
CROMPTON IN	Weak lighting business dims performance
DIXON IN	Dull Q3 as mobiles business dials down
HAVL IN	Modest performance amid a challenging environment
KEII IN	Upbeat numbers
ORIENTEL IN	Back on track with Q3 rebound
POLYCAB IN	Buoyant quarter
SYRMA IN	Strong topline but margins soften
VGRD IN	Topline intact while margin pressure persists
VOLT IN	Subpar quarter as EMP losses deepen

Source: BOBCAPS Research



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%

HOLD – Expected return from -6% to +15%

SELL – Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017. BOBCAPS CIN Number: U65999MH1996GOI098009.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.